Marc Brummer

Marc Brummer currently serves as an Analyst at BDC Venture Capital, where he is responsible for identifying, funding, and partnering with innovative technology entrepreneurs operating throughout the Canadian market. In this investment role, he evaluates early-stage and growth-stage opportunities to provide strategic capital that drives the commercial expansion of domestic technology enterprises. Brummer was notably associated with BDC Venture Capital's participation in a $32.0 million equity financing round for Congruence Therapeutics, a transaction projected for September 2025. This significant funding event involved a syndicate of prominent institutional co-investors, specifically including Alexandria Venture Investments, Investissement Québec, and the global healthcare investment firm OrbiMed. Through these collaborative financial partnerships, he actively supports the operational scaling and strategic development of high-potential portfolio companies. His current focus remains dedicated to strengthening the Canadian technology ecosystem by executing targeted venture capital investments.